List of Excipients in Branded Drug CABINET ALLERGY RELIEF FEXOFENADINE

Generic Drugs Containing CABINET ALLERGY RELIEF FEXOFENADINE

Company	Ingredient	NDC	Excipient
Cabinet Health PBC	fexofenadine hydrochloride	82725-3002	CELLULOSE, MICROCRYSTALLINE
Cabinet Health PBC	fexofenadine hydrochloride	82725-3002	CROSCARMELLOSE SODIUM
Cabinet Health PBC	fexofenadine hydrochloride	82725-3002	MAGNESIUM STEARATE
Cabinet Health PBC	fexofenadine hydrochloride	82725-3002	SILICON DIOXIDE

What are the Most Frequently-Used Excipients in CABINET ALLERGY RELIEF FEXOFENADINE?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	CROSCARMELLOSE SODIUM
1	MAGNESIUM STEARATE
1	SILICON DIOXIDE

Excipient Strategy and Commercial Opportunities for Fexofenadine in Cabinet Allergy Relief

Last updated: March 5, 2026

What are the key considerations for excipient selection in Fexofenadine formulations?

Fexofenadine, a second-generation antihistamine, often formulated as tablets or orally disintegrating tablets (ODT), requires excipients that optimize stability, bioavailability, and patient compliance.

Common excipients in Fexofenadine formulations:

• Disintegrants: Crospovidone, Croscarmellose sodium, or sodium starch glycolate to facilitate rapid dissolution in ODTs.
• Fillers/binders: microcrystalline cellulose (MCC) to ensure tablet integrity.
• Lubricants: E.g., magnesium stearate to enable tablet manufacturing.
• Flow agents: Silica derivatives to improve powder flow during production.
• Sweeteners and flavoring agents: Mannitol, aspartame, and mint flavor for palatability in ODTs.

Stability considerations:

Fexofenadine's stability is sensitive to moisture, making the selection of hydrophobic excipients advantageous. In formulations with less moisture exposure, standard excipients remain effective.

Compatibility issues:

Some excipients may interact with Fexofenadine, affecting bioavailability. For example, aluminum and magnesium compounds reduce absorption, necessitating either coating or timing considerations.

What are the emerging strategies in excipient design for Fexofenadine products?

• Use of bioequivalent excipients: Innovations focus on creating formulations with improved disintegration times and enhanced patient experience.
• Mucoadhesive excipients: Explore for localized allergy relief formulations.
• Plasticizers and stabilizers: Reduce moisture sensitivity and improve shelf life.
• Taste-masking agents: Improve acceptance, especially in pediatric formulations.

Which commercial opportunities exist for excipient innovation?

Market size and growth

The global antihistamine market was valued at approximately USD 4.12 billion in 2021, with a Compound Annual Growth Rate (CAGR) of around 8% projected through 2027 ([1]). Fexofenadine accounts for about 15-20% of this market.

Opportunities for formulation differentiation:

• Enhanced ODT formats: Faster disintegration and improved taste-masking can command premium pricing.
• Multi-layer tablets: Combine antihistamines with decongestants, requiring specialized excipients.
• Chewable or melt-in-mouth variants: Target pediatric and geriatric segments.

Excipient supplier market

Suppliers offering high-quality, pharmaceutical-grade excipients, such as FMC, DuPont, and Meggle, see increased demand. Opportunities exist in developing proprietary excipients that improve stability and bioavailability.

Regulatory and patent considerations:

Innovative excipients that demonstrate clear benefits may be patentable, providing a competitive advantage. Regulatory pathways for excipient approval vary but generally require demonstration of safety and quality.

What are potential barriers and challenges?

• Regulatory approval delays: New excipients require extensive safety data.
• Cost of formulation development: Especially when exploring novel excipients.
• Market entry barriers: Existing strong incumbents with proven formulations.

Key Takeaways

• Correct excipient choices can optimize Fexofenadine's efficacy, stability, and patient compliance.
• Emerging excipient technologies aim to improve disintegration and taste, particularly for ODTs.
• The market for antihistamine formulations, including Fexofenadine, presents growth opportunities, especially via innovative dosage forms.
• Patentability and regulatory approval are critical considerations in excipient strategy.
• Strategic partnerships with excipient suppliers can enhance formulation development.

FAQs

What excipients are most critical for Fexofenadine tablet stability?
Hydrophobic excipients like microcrystalline cellulose and specialized stabilizers prevent moisture ingress, preserving drug stability.

Can novel excipients reduce Fexofenadine's interaction with antacids?
Indirectly. Encapsulation or coating with specific excipients can mitigate interactions, improving bioavailability.

Are there excipient strategies to improve pediatric Fexofenadine formulations?
Yes. Taste-masking agents, rapid-disintegration excipients, and chewable formats enhance acceptance.

What regulatory hurdles exist for excipient innovation in antihistamine drugs?
Safety data submissions and compliance with pharmacopeial standards are required, potentially prolonging approval.

How can excipient innovation create a competitive advantage for Fexofenadine products?
Formulations with better stability, faster disintegration, or improved taste can justify premium pricing and market share growth.

---

References

[1] Grand View Research. (2022). Antihistamines Market Size, Share & Trends Analysis Report.
[2] USP-NF. (2021). Pharmacopeial standards for excipients.
[3] Kiem, T., et al. (2020). Advances in pharmaceutical excipient technology. International Journal of Pharmaceutics.